FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014335547> ?p ?o ?g. }

• W3014335547 abstract "Abstract Background Besides modeling/simulation-based analysis, no post-approval studies have evaluated optimal administration frequency of pembrolizumab in non-small cell lung cancer (NSCLC). Patients and Methods We performed a multicenter retrospective cohort study to evaluate association between survival outcomes and treatment extensions/delays of pembrolizumab-based regimens in advanced NSCLC patients. Those who had received at least four cycles in routine practice were divided into two groups: non-standard (Non-Std: ≥2 cycles at intervals >3weeks ±3days) and standard (Std: all cycles every 3weeks or 1 cycle >3weeks ±3days). Results Among 150 patients, 92 (61%) were eligible for the study (Non-Std:27, Std:65). Reasons for patients with extensions/delays in the Non-Std group included: immune-related adverse events (irAEs,33%), non-irAE-related medical issues (26%), and patient-physician preference (41%). Non-Std group was more likely to have higher PD-L1 tumor proportion score, higher number of treatment cycles and pembrolizumab monotherapy. Univariate and 6-month landmark analyses showed longer median overall survival (OS) and progression-free survival (PFS) in Non-Std group compared to the Std group. After multivariable adjustment for confounding factors, there was no significant difference in OS [HR 1.1 (95%C.I.: 0.3–4.7), p=0.874] or PFS [HR 2.7 (95%C.I.: 0.8–8.8), p=0.094] between the two groups. Conclusion Our study shows that a significant proportion of advanced NSCLC patients receive pembrolizumab-based regimens with extended intervals or delays in routine clinical practice and with similar outcomes to those receiving treatment at label-specified 3-week intervals. Given the durability of benefit seen and the potential for cost reduction and decreased infusion frequency in these patients, this requires validation in prospective trials. MicroAbstract The most cost-effective administration frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) is unknown. We found that a significant proportion of these patients receive pembrolizumab-based regimens with extended intervals or delays in routine practice, with similar outcomes to those on label-specified 3-week interval treatments. Prospective evaluation of alternative dosing strategies is warranted to develop a more fiscally viable and patient-centered model." @default.
• W3014335547 created "2020-04-10" @default.
• W3014335547 creator A5005786694 @default.
• W3014335547 creator A5010805361 @default.
• W3014335547 creator A5018612915 @default.
• W3014335547 creator A5041855112 @default.
• W3014335547 creator A5042156692 @default.
• W3014335547 creator A5043119087 @default.
• W3014335547 creator A5044257132 @default.
• W3014335547 creator A5044949497 @default.
• W3014335547 creator A5048644068 @default.
• W3014335547 creator A5053039908 @default.
• W3014335547 creator A5055688102 @default.
• W3014335547 creator A5057898983 @default.
• W3014335547 creator A5061742224 @default.
• W3014335547 creator A5066642925 @default.
• W3014335547 creator A5080669646 @default.
• W3014335547 date "2020-04-02" @default.
• W3014335547 modified "2023-09-27" @default.
• W3014335547 title "Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer" @default.
• W3014335547 cites W1081778167 @default.
• W3014335547 cites W1990675339 @default.
• W3014335547 cites W2041167828 @default.
• W3014335547 cites W2115068885 @default.
• W3014335547 cites W2150048477 @default.
• W3014335547 cites W2342481353 @default.
• W3014335547 cites W2587297698 @default.
• W3014335547 cites W2592144107 @default.
• W3014335547 cites W2620733650 @default.
• W3014335547 cites W2621194109 @default.
• W3014335547 cites W2770706047 @default.
• W3014335547 cites W2888888880 @default.
• W3014335547 cites W2890930659 @default.
• W3014335547 cites W2891290839 @default.
• W3014335547 cites W2893221436 @default.
• W3014335547 cites W2903486314 @default.
• W3014335547 cites W2945674342 @default.
• W3014335547 cites W2947713025 @default.
• W3014335547 cites W2947873015 @default.
• W3014335547 cites W2950711263 @default.
• W3014335547 cites W2971924586 @default.
• W3014335547 cites W3003992911 @default.
• W3014335547 cites W4210394199 @default.
• W3014335547 doi "https://doi.org/10.1101/2020.03.31.20048637" @default.
• W3014335547 hasPublicationYear "2020" @default.
• W3014335547 type Work @default.
• W3014335547 sameAs 3014335547 @default.
• W3014335547 citedByCount "1" @default.
• W3014335547 countsByYear W30143355472020 @default.
• W3014335547 crossrefType "posted-content" @default.
• W3014335547 hasAuthorship W3014335547A5005786694 @default.
• W3014335547 hasAuthorship W3014335547A5010805361 @default.
• W3014335547 hasAuthorship W3014335547A5018612915 @default.
• W3014335547 hasAuthorship W3014335547A5041855112 @default.
• W3014335547 hasAuthorship W3014335547A5042156692 @default.
• W3014335547 hasAuthorship W3014335547A5043119087 @default.
• W3014335547 hasAuthorship W3014335547A5044257132 @default.
• W3014335547 hasAuthorship W3014335547A5044949497 @default.
• W3014335547 hasAuthorship W3014335547A5048644068 @default.
• W3014335547 hasAuthorship W3014335547A5053039908 @default.
• W3014335547 hasAuthorship W3014335547A5055688102 @default.
• W3014335547 hasAuthorship W3014335547A5057898983 @default.
• W3014335547 hasAuthorship W3014335547A5061742224 @default.
• W3014335547 hasAuthorship W3014335547A5066642925 @default.
• W3014335547 hasAuthorship W3014335547A5080669646 @default.
• W3014335547 hasBestOaLocation W30143355471 @default.
• W3014335547 hasConcept C121608353 @default.
• W3014335547 hasConcept C126322002 @default.
• W3014335547 hasConcept C143998085 @default.
• W3014335547 hasConcept C144301174 @default.
• W3014335547 hasConcept C167135981 @default.
• W3014335547 hasConcept C197934379 @default.
• W3014335547 hasConcept C2776256026 @default.
• W3014335547 hasConcept C2777288759 @default.
• W3014335547 hasConcept C2777701055 @default.
• W3014335547 hasConcept C2780057760 @default.
• W3014335547 hasConcept C38180746 @default.
• W3014335547 hasConcept C71924100 @default.
• W3014335547 hasConcept C72563966 @default.
• W3014335547 hasConcept C77350462 @default.
• W3014335547 hasConceptScore W3014335547C121608353 @default.
• W3014335547 hasConceptScore W3014335547C126322002 @default.
• W3014335547 hasConceptScore W3014335547C143998085 @default.
• W3014335547 hasConceptScore W3014335547C144301174 @default.
• W3014335547 hasConceptScore W3014335547C167135981 @default.
• W3014335547 hasConceptScore W3014335547C197934379 @default.
• W3014335547 hasConceptScore W3014335547C2776256026 @default.
• W3014335547 hasConceptScore W3014335547C2777288759 @default.
• W3014335547 hasConceptScore W3014335547C2777701055 @default.
• W3014335547 hasConceptScore W3014335547C2780057760 @default.
• W3014335547 hasConceptScore W3014335547C38180746 @default.
• W3014335547 hasConceptScore W3014335547C71924100 @default.
• W3014335547 hasConceptScore W3014335547C72563966 @default.
• W3014335547 hasConceptScore W3014335547C77350462 @default.
• W3014335547 hasLocation W30143355471 @default.
• W3014335547 hasLocation W30143355472 @default.
• W3014335547 hasOpenAccess W3014335547 @default.
• W3014335547 hasPrimaryLocation W30143355471 @default.
• W3014335547 hasRelatedWork W1971557041 @default.
• W3014335547 hasRelatedWork W1974023271 @default.

• next